Anti-autoimmune antibodies for treatment of pemphigus
View Patent ↗This invention relates to compositions and methods for the use of anti-autoimmune reagents that specifically bind to anti-desmoglein antibodies, which are responsible for both pemphigus vulgaris and pemphigus foliaceus. In addition, the invention relates to methods and compositions for inhibiting the expression or function of a variable region of an anti-desmoglein (anti-Dsg) pathogenic autoantibody.
1. A method of inhibiting the binding of an anti-desmoglein autoantibody or fragment thereof to desmoglein, said method comprising contacting the anti-desmoglein autoantibody or fragment thereof with a composition comprising an anti-autoimmune reagent that specifically binds to an anti-desmoglein autoantibody or fragment thereof, wherein the anti-autoimmune reagent is a peptide comprising the amino acid sequence of SEQ ID NO: 171.
2. The method of claim 1 , wherein the anti-desmoglein (Dsg) autoantibody or fragment thereof binds to a target molecule selected from the group consisting of Dsg1, Dsg3, and any combination thereof
3. The method of claim 1 , wherein the anti-desmoglein autoantibody or fragment thereof is associated with the pathology of pemphigus vulgaris (PV), or pemphigus foliaceus (PF).
4. The method of claim 1 , wherein the anti-autoimmune reagent specifically binds to a variable region of a heavy chain (V H ) of the anti-desmoglein autoantibody or fragment thereof.
5. The method of claim 4 , wherein the heavy chain (V H ) of the anti-desmoglein autoantibody or fragment thereof is encoded by a gene selected from the group consisting of VH3-8, VH3-07, VH1-4M28, and any combination thereof.
6. The method of claim 1 , wherein the anti-autoimmune reagent is linked to a B cell superantigen.
7. The method of claim 6 , wherein linking the anti-autoimmune reagent to a B cell superantigen affects V H -targeted B-cell deletion.